Hämatopathologie Hamburg

Name

Hämatopathologie Hamburg

Legal name

MVZ HPH Institut für Pathologie und Hämatopathologie GmbH

Website

https://haematopathologie-hamburg.de

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Diagnostic Pathology and Hematopathology Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Hematopathology diagnostics
• Molecular pathology testing
• Cancer diagnostic services
• Liquid biopsy analysis
• Minimal residual disease

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Laboratory Services: B2B laboratory diagnostic testing services for hospitals, organ centers, and outpatient hemato-oncology physicians. Services include histology, molecular pathology, immunochemistry, FACS analysis, cytology, and specialized cancer diagnostics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Hämatopathologie Hamburg operates a specialized diagnostic laboratory group in Hamburg, Germany, providing comprehensive pathology and hematopathology services for solid tumors and hematological neoplasias. The practice delivers molecular pathology, liquid biopsy, MRD testing, immunohistochemistry, histology, FACS analysis, cytology, and molecular tumor board services across five locations, with electronic report delivery to referring physicians. It launched HPH MRD, Germany's first tumor-informed MRD test, in partnership with Haystack MRD technology.

Product overview

Hämatopathologie Hamburg operates as a diagnostic laboratory group offering a comprehensive portfolio of pathology and hematopathology services. Their core offering includes HPH MRD, a next-generation tumor-informed ctDNA-based minimal residual disease test for solid tumor cancer patients, based on licensed Haystack MRD technology from Quest Diagnostics. The portfolio spans the full spectrum of morphological tissue diagnostics, molecular pathology, and gynecological cytology across five locations. The diagnostic services include molecular pathology, liquid biopsy, MRD testing (for both solid tumors and hematological neoplasms), HRD/GIS testing, FACS analysis, immunohistochemistry, histology, CISH/FISH, cytology, and molecular tumor board consultations. They provide integrated workflow from sample collection through electronic result delivery, serving hospitals, cancer centers, and outpatient hemato-oncologists.

Differentiator

Problem solved

Functional benefit

Brands

• HPH MRD: A tumor-informed MRD test for high-precision ctDNA detection in solid tumor cancer patients, based on Haystack MRD technology from Haystack Oncology (Quest Diagnostics subsidiary). First MRD test evaluated in Germany.

Products and services

• Molekularpathologie (Molecular Pathology) Molecular pathology testing that characterizes genetic alterations in solid tumors and hematological neoplasias to support diagnosis, prognosis, and therapy selection for hospital and outpatient oncologists.
• Liquid-Biopsy Blood-based ctDNA testing for non-invasive tumor profiling, therapy monitoring, and recurrence detection in oncology patients, supporting treating physicians at hospitals and outpatient practices.
• MRD-Testung (Minimal Residual Disease Testing) MRD diagnostics measuring residual disease burden in hematological neoplasias and solid tumors to guide treatment intensity and surveillance decisions for hemato-oncologists.
• HRD / GIS Testing HRD and GIS testing to identify tumors with homologous recombination repair deficiency, supporting PARP inhibitor therapy decisions in ovarian, breast, prostate, and other solid tumor patients.
• FACS-Analyse (Flow Cytometry) Multiparameter flow cytometry immunophenotyping of blood, bone marrow, and tissue samples to support diagnosis and classification of leukemias, lymphomas, and other hematological disorders.
• Immunhistochemie (Immunohistochemistry) Antibody-based tissue staining and interpretation to support tumor classification, biomarker detection, and therapy-relevant diagnostics in histopathology cases.
• Histologie (Histology) Conventional histology processing, embedding, sectioning, and staining of tissue specimens to support routine and complex pathological diagnosis.
• CISH / FISH In situ hybridization (chromogenic and fluorescence-based) assays on tissue and cell preparations to detect specific chromosomal alterations and gene rearrangements in tumors.
• Zytologie (Cytology) Non-gynecological and general cytology examination of fine-needle aspirates, fluid, and exfoliative samples to support cancer and infectious disease diagnosis.
• Gynäkologische Zytologie (Gynecological Cytology) Gynecological cytology screening and diagnostic services, including conventional and thin-layer Pap test evaluation, for gynecologists and screening programs.
• Molekulares Tumorboard (Molecular Tumor Board) Multidisciplinary case review combining pathology, molecular diagnostics, and clinical oncology to recommend individualized therapy for complex cancer patients.
• HPH MRD (Tumor-informed MRD Test) Germany's first commercial tumor-informed MRD test, based on Haystack MRD technology, using tumor-specific ctDNA signatures to detect and quantify minimal residual disease in solid tumor patients after curative-intent therapy.

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core, strong and moderate.

• Quest Diagnostics (Haystack Oncology)coreTechnology or Integration · 17 October 2025Licensing partnership for Haystack MRD technology enabling HPH MRD ctDNA blood test for cancer monitoring in Europe. HPH brings localized MRD testing to Germany based on Quest Diagnostics' Haystack MRD technology for detecting residual disease in solid tumor cancer patients.
• Institut für Tumorgenetik NordstrongStrategic or Co-development PartnerStrategic partner in tumor genetics diagnostics, part of the strong partner network.
• MVZ - Hanse Histologikum GmbHstrongStrategic or Co-development PartnerPathology partner collaboration in Hamburg region for comprehensive diagnostic services.
• ForGen Forensische Genetik und Rechtsmedizin am Institut für Hämatopathologie Hamburg GmbHstrongStrategic or Co-development PartnerForensic genetics and legal medicine division operating within the HPH group structure.
• Lungenkrebsmedizin Oldenburg GbR (NOWEL)moderateStrategic or Co-development PartnerLung cancer medicine partnership for specialized oncology diagnostics and treatment support.
• medtoday by art tempi communications gmbhmoderateGTM or Marketing PartnerEvent organizer for the OncoPatho Best Practice conference - interdisciplinary scientific event for oncology and pathology professionals.

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Broad incumbents

• Synlab: Europe's largest medical diagnostics services group, operating clinical labs across Germany and ~30 countries. Synlab is the most direct broad incumbent competitor for hospital lab contracts and outpatient diagnostic samples in the same German oncology/hematology space as HPH.
• Unilabs: Pan-European clinical laboratory and diagnostics provider with operations across multiple countries including Germany. Unilabs competes for hospital and outpatient diagnostic volume in the same oncology/hematology specialty testing categories as HPH.
• Sonic Healthcare Germany: Sonic Healthcare operates a large European clinical laboratory network (including German lab brands) providing pathology, molecular diagnostics, and hospital lab services. Comparable as a broad incumbent in the same German specialty diagnostics market.
• Cerba Healthcare: European specialty clinical laboratory and diagnostic services group with strong positions in oncology, genetics, and routine clinical pathology. Comparable as a European specialty lab peer competing for the same molecular and oncology testing volume.

Direct peers

• Amedes Group: German-headquartered medical laboratory group offering clinical diagnostics including pathology, molecular pathology, and human genetics. Amedes competes head-to-head with HPH for hospital tenders and outpatient oncology work in Germany and is the closest direct peer by service mix and scale.
• LADR Laborverbund Deutscher Ärzte: Physician-owned network of medical laboratories in Germany offering clinical chemistry, microbiology, pathology, and molecular diagnostics. Directly comparable regional German lab network with a similar B2B go-to-market and physician-led governance model.

Regional players

• Medicover (Diagnostic Services): European diagnostics and healthcare services provider operating laboratories in Central/Eastern Europe. Comparable as a regional clinical lab peer in similar specialty diagnostics, though primarily outside HPH's German catchment.

Emerging players

• MVZ Medizinische Genetik Mainz / Genomic laboratories in Germany: German specialty MVZ/genetic lab focused on molecular genetics and oncology diagnostics. Comparable as a smaller specialty German lab competing for outpatient molecular pathology and hereditary cancer testing volume.

Others

• Helios Klinikum (Hospital-affiliated pathology): Helios operates in-house pathology services across its German hospital network. Comparable as a customer/competitor dynamic: Helios hospital labs may outsource complex molecular and MRD work to HPH, but can also choose to internalize, making it both customer and competitive substitute.
• Charité Comprehensive Cancer Center (Molecular Pathology): University hospital molecular pathology department providing high-complexity oncology diagnostics including NGS, liquid biopsy, and molecular tumor boards. Comparable as an academic reference site whose clinical guidelines and validation work shape HPH's outpatient referral funnel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hämatopathologie Hamburg